Lipella Pharmaceuticals (LIPO) Stock Forecast, Price Target & Predictions
LIPO Stock Forecast
Lipella Pharmaceuticals stock forecast is as follows: an average price target of $2.00 (represents a 392.85% upside from LIPO’s last price of $0.41) and
LIPO Price Target
Lipella Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 09, 2024 | Jason McCarthy | Maxim Group | $2.00 | $0.70 | 183.93% | 392.85% |
The latest Lipella Pharmaceuticals stock forecast, released on Apr 09, 2024 by Jason McCarthy from Maxim Group, set a price target of $2.00, which represents a 183.93% increase from the stock price at the time of the forecast ($0.70), and a 392.85% increase from LIPO last price ($0.41).
Lipella Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $0.41 | $0.41 | $0.41 |
| Upside/Downside | -100.00% | -100.00% | 392.85% |
In the current month, the average price target of Lipella Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lipella Pharmaceuticals's last price of $0.41. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Lipella Pharmaceuticals Financial Forecast
Lipella Pharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | $238.77M |
| Avg Forecast | $142.50M | $139.43M | $136.00K | $146.00K | $120.84K |
| High Forecast | $142.50M | $139.43M | $136.00K | $146.00K | $120.84K |
| Low Forecast | $142.50M | $139.43M | $136.00K | $146.00K | $120.84K |
| # Analysts | - | - | - | - | - |
| Surprise % | - | - | - | - | 1975.90% |
Lipella Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 0 analysts is $146.00K, with a low forecast of $146.00K, and a high forecast of $146.00K. LIPO's average Quarter revenue forecast represents a -99.94% decrease compared to the company's last Quarter revenue of $238.77M (Dec 23).
Lipella Pharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - |
| EBITDA | - | - | - | - | $-4.70B |
| Avg Forecast | $-89.30M | $-87.38M | $-85.22K | $-91.49K | $-75.72K |
| High Forecast | $-89.30M | $-87.38M | $-85.22K | $-91.49K | $-75.72K |
| Low Forecast | $-89.30M | $-87.38M | $-85.22K | $-91.49K | $-75.72K |
| Surprise % | - | - | - | - | 62008.48% |
undefined analysts predict LIPO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lipella Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Lipella Pharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - |
| Net Income | - | - | - | - | $-4.63B |
| Avg Forecast | $-1.06M | $-912.68K | $-912.68K | $-1.22M | $12.64M |
| High Forecast | $-1.06M | $-912.68K | $-912.68K | $-1.22M | $12.64M |
| Low Forecast | $-1.06M | $-912.68K | $-912.68K | $-1.22M | $12.64M |
| Surprise % | - | - | - | - | -365.91% |
Lipella Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LIPO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lipella Pharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - |
| SG&A | - | - | - | - | $2.15B |
| Avg Forecast | $254.51M | $249.03M | $242.90K | $260.76K | $215.82K |
| High Forecast | $254.51M | $249.03M | $242.90K | $260.76K | $215.82K |
| Low Forecast | $254.51M | $249.03M | $242.90K | $260.76K | $215.82K |
| Surprise % | - | - | - | - | 9984.82% |
Lipella Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $260.76K, based on 0 Wall Street analysts, with a range of $260.76K to $260.76K. The forecast indicates a -99.99% fall compared to LIPO last annual SG&A of $2.15B (Dec 23).
Lipella Pharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - |
| EPS | - | - | - | - | $-770.65 |
| Avg Forecast | $-0.14 | $-0.12 | $-0.12 | $-0.16 | $2.09 |
| High Forecast | $-0.14 | $-0.12 | $-0.12 | $-0.16 | $2.09 |
| Low Forecast | $-0.14 | $-0.12 | $-0.12 | $-0.16 | $2.09 |
| Surprise % | - | - | - | - | -369.01% |
According to undefined Wall Street analysts, Lipella Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LIPO previous annual EPS of $NaN (undefined).
Lipella Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LIPO | Lipella Pharmaceuticals | $0.41 | $2.00 | 387.80% | - |
| FENC | Fennec Pharmaceuticals | $5.26 | $15.75 | 199.43% | Buy |
| ACRV | Acrivon Therapeutics | $7.60 | $22.00 | 189.47% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| ELVN | Enliven Therapeutics | $21.47 | $33.00 | 53.70% | Buy |
LIPO Forecast FAQ
Will Lipella Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for LIPO stock, the company can go up by 392.85% (from the last price of $0.406 to the average price target of $2), up by 392.85% based on the highest stock price target, and up by 392.85% based on the lowest stock price target.
Can Lipella Pharmaceuticals stock reach $1?
LIPO's average twelve months analyst stock price target of $2 supports the claim that Lipella Pharmaceuticals can reach $1 in the near future.
What are Lipella Pharmaceuticals's analysts' financial forecasts?
LIPO's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $282.22M (high $282.22M, low $282.22M), average EBITDA is $-177M (high $-177M, low $-177M), average net income is $-4.107M (high $-4.107M, low $-4.107M), average SG&A $504.05M (high $504.05M, low $504.05M), and average EPS is $-0.54 (high $-0.54, low $-0.54).
Did the LIPO's actual financial results beat the analysts' financial forecasts?
Based on Lipella Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $449.62M, beating the average analysts forecast of $120.84K by 371970.14%. Apple's EBITDA was $-4.746B, beating the average prediction of $-75.725K by 6267252.92%. The company's net income was $-4.619B, missing the average estimation of $12.64M by -36633.36%. Apple's SG&A was $2.16B, beating the average forecast of $215.82K by 999197.58%. Lastly, the company's EPS was $-769, missing the average prediction of $2.09 by -36942.86%. In terms of the last quarterly report (Dec 2023), Lipella Pharmaceuticals's revenue was $238.77M, beating the average analysts' forecast of $120.84K by 197490.20%. The company's EBITDA was $-4.696B, beating the average prediction of $-75.725K by 6200748.10%. Lipella Pharmaceuticals's net income was $-4.626B, missing the average estimation of $12.64M by -36690.96%. The company's SG&A was $2.15B, beating the average forecast of $215.82K by 998381.87%. Lastly, the company's EPS was $-771, missing the average prediction of $2.09 by -37001.28%